At Amgen, our values are more than words. They guide how we collaborate, innovate, and work together to serve patients worldwide. From supporting one another to solving complex challenges as one team, our people are united by a shared purpose: making a meaningful impact on patients’ lives. Discover what it means to work at Amgen and build a career driven by purpose. Explore opportunities: https://careers.amgen.com/ #LifeAtAmgen #AmgenCareers
About us
Amgen harnesses the best of biology and technology to fight the world’s toughest diseases, and make people’s lives easier, fuller and longer. We helped establish the biotechnology industry, and we remain on the cutting-edge of innovation, using technology and human genetic data to push beyond what’s known today. Our investment in research and development has yielded a robust pipeline that builds on our existing portfolio of medicines to treat cancer, heart disease, osteoporosis, inflammatory diseases and rare diseases. Amgen is one of 30 companies comprising the Dow Jones Industrial Average®, and part of the Nasdaq-100 Index®. In 2024, Amgen was named one of the “World’s Most Innovative Companies” by Fast Company and one of “America’s Best Large Employers” by Forbes. For more information, visit Amgen.com and follow us on X, LinkedIn, Instagram, TikTok, YouTube and Threads. 🔗 Community Guidelines: https://wwwext.amgen.com/community-guidelines 🔗Global Privacy Statement Directory: www.amgen.com/dp Special Advisory: Please be cautious of scam recruitment offers claiming to be from Amgen. Such scams may come from various sources, including fake websites and/or unsolicited emails and seek to obtain personal data or payment from victims by offering jobs that do not exist. Please be advised that Amgen would never ask for payment to progress a job application. When in doubt, please check to see if the position in question is posted on this website before applying. Additionally, please report any suspicious recruiting activity to https://complaint.ic3.gov/ and thank you for your assistance.
- Website
-
http://www.amgen.com
External link for Amgen
- Industry
- Biotechnology Research
- Company size
- 10,001+ employees
- Headquarters
- Thousand Oaks, CA
- Type
- Public Company
- Founded
- 1980
- Specialties
- Biologics, Human therapeutics, and Development of novel products
Locations
Employees at Amgen
Updates
-
Former medical correspondent Dr. Nancy Snyderman shares how she was diagnosed with cardiovascular disease without experiencing symptoms. Now, Nancy is encouraging women to take a closer look at their cardiovascular health, including understanding LDL (“bad”) cholesterol and its role in long-term risk. At Amgen, we’re committed to sharing personal stories like Nancy’s to inspire more conversations about cardiovascular health and prompt earlier action to lower high LDL-C. 🎥 Watch her story now.
Watch Nancy's Story
-
Congratulations to Amgen Golf Ambassador Shane Lowry on winning the 2026 Amgen Irish Open. To see an Amgen ambassador lift the trophy made an already memorable week even more meaningful for our people and partners. Shane's performance reflected not only exceptional sporting achievement, but the pride, resilience and connection to community that make him such a valued ambassador for Amgen and Irish sport. Beyond the course, Shane has consistently embraced the wider purpose of the Amgen Irish Open, including his support for Make-A-Wish Ireland, the tournament's charity partner. His commitment to giving back, inspiring others and championing communities in Ireland is something we are proud to support. DP World Tour
-
-
SCLC NEWS: The FDA approved a label update to the administration information for Amgen’s DLL3-targeting T-cell engager for certain patients with extensive-stage small cell lung cancer (ES-SCLC). 🔗Learn more: https://amgen.ly/4h6jiQK
-
-
The story of innovation in small cell lung cancer (SCLC) isn’t told through a single discovery. It’s written through years of research, collaboration, and scientific exchange. As the oncology community comes together at #WCLC26 this weekend, we’re proud to share new data across several studies in small cell lung cancer. Learn more here: amgen.ly/4xWu4Ao
-
What happens when you bring 130+ advocacy organizations together and ask them for their insights about their patient communities? You listen. At the 2026 Amgen Advocacy Summit, our own Michelle Rivas Notestine went straight to the source, asking advocates what they’re seeing in their communities, what they’re learning and where there’s an opportunity to turn insight into impact. Watch what we heard. And more importantly, what could come next.
-
📢 SCLC update: Amgen announced that a global Phase 3 study evaluating its DLL3-targeting therapy as a first-line maintenance treatment for people with extensive-stage small cell lung cancer met its primary endpoint ➡️ Learn more: https://amgen.ly/4xbWEMQ
-
At Amgen, sustainability isn’t a standalone initiative. From reducing energy and water use throughout our processes to improving the efficiency of how we make medicines, sustainability is built into our operations. Learn more about how we’re advancing environmental sustainability: https://amgen.ly/3VcN5Qq
-
Visits to multiple specialists. Years of waiting. And still, no clear diagnosis. For many people living with Thyroid Eye Disease (TED), the path to answers can be long and complex. Greater awareness and earlier recognition of this disease could help shorten the time to diagnosis and connect patients with appropriate care sooner. So, what will it take to shorten that journey? At European Thyroid Association's Annual Meeting, we’re sharing our latest advances in TED and engaging with the medical community to better understand educational gaps and underscore how multidisciplinary collaboration could lead to earlier diagnoses for people living with TED. Hear more from Dr. Bobby Korn, MD, PhD, Dr. Colin Dayan, Dr. Diego Strianese and Amgen’s Georgia Pontikes, M.B.A. on the impact of TED, the importance of recognizing it sooner and what progress could mean for the TED community.